


# ***Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Biological and Therapeutic Continuum***

Michael Lübbert

Steven D. Gore

in collaboration with

Carlo Aul, Hartmut Bertz, Clara D. Bloomfield, Rainer Claus, Barbara Deschler-Baier, Christiane Dobbelsstein, Christian Flotho, Jürgen Finke, Paul Fisch, Arnold Ganser, Norbert Gattermann, Ulrich Germing, Aristoteles Giagounidis, Peter Haas, Detlef Haase, Björn Hackanson, Wolf-Karsten Hofmann, Tina Jöckel, H. Phillip Koeffler, Andrea Kündgen, Hilda Mangos, Reinhard Marks, Krzysztof Mrózek, Michael J. Müller, Uwe Platzbecker, Björn Rüter, Valeria Santini, Mikkael A. Sekeres, Annette Schmitt-Gräff, Dominik Schnerch, Lewis R. Silverman, Laura Simons, Christian Steidl, Juliane Steinmann, Felicitas Thol, Pierre Wijermans, Theo de Witte, Yataro Yoshida



# **Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Biological and Thera- peutic Continuum**



**UNI-MED Verlag AG**  
**Bremen - London - Boston**

**Lübbert, Michael:**

Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Biological and Therapeutic Continuum/

Michael Lübbert and Steven Gore-

1<sup>st</sup> edition - Bremen: UNI-MED, 2014 (UNI-MED SCIENCE)

ISBN 978-3-8374-5271-6

© 2014      by UNI-MED Verlag AG, D-28323 Bremen,  
International Medical Publishers (London, Boston)  
Internet: [www.uni-med.de](http://www.uni-med.de), e-mail: [info@uni-med.de](mailto:info@uni-med.de)

Printed in Europe

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way and storage in data banks. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

## ***MEDICINE - STATE OF THE ART***

---

UNI-MED Verlag AG, one of the leading medical publishing companies in Germany, presents its highly successful series of scientific textbooks, covering all medical subjects. The authors are specialists in their fields and present the topics precisely, comprehensively, and with the facility of quick reference in mind. The books will be most useful for all doctors who wish to keep up to date with the latest developments in medicine.

## ***Preface and acknowledgements***

---

The advent of genotype-driven treatment approaches, developed for the specific therapy of genetically defined subgroups of AML and - more recently - also MDS, has been boosted by the rapid and massive advances in high-throughput DNA sequencing technology. Thus at present the biological and therapeutic continuum existing between MDS and AML has become even more evident. This book has the goal of updating the reader on the epidemiological, morphological, cytogenetic and molecular aspects of both groups of disorders, pointing out the common themes and the distinctions between them. Furthermore, in separate chapters the different treatment options are reviewed: those with curative intent (standard chemotherapy, allografting) and the more recent treatment principles such as epigenetically active drugs, kinase inhibitors, differentiating agents and anti-angiogenic compounds among others. These non-intensive therapies may prove to be increasingly useful as well-tolerated "bridging" treatments prior to the curative approach of allografting. State-of-the-art functional and psycho-social assessment instruments used to determine the "fitness" of these often older patients are also reviewed, since they are increasingly applied prior to the choice of treatment modality.

The previous two editions of this book were authored by a group of experts in the fields of MDS and AML, joined in the German MDS Study Group and Competence Network "Acute and Chronic Leukemias". The present edition is also strongly supported by a number of international experts, many of them involved in the European LeukemiaNet - underscoring that with the increasingly differentiated diagnostics and treatment of the growing number of sub-entities, success is only possible within large, international networks.

We wish to thank all the contributing authors for their dedicated work on the different chapters, and thank Juliane Steinmann for excellent editorial support, as well as Dr. Birte Peters from UNI-MED Publishing Company for support of this project.

*January 2014  
Freiburg, Germany  
New Haven, CN, USA*

*Michael Lübbert  
Steven D. Gore*

# Authors

---

## Editors:

Michael Lübbert, MD  
Professor, Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

Steven D. Gore, MD  
Professor of Medicine, MYSM School of Medicine  
Cancer Center  
25 York St  
New Haven, CT 06510-3221  
USA

## Authors:

Carlo Aul, MD  
Professor, St. Johannes Hospital Duisburg  
An der Abtei 7-11  
47166 Duisburg  
Germany  
*Chapters 7., 8.*

Hartmut Bertz, MD  
Professor, Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany  
*Chapter 10.*

Clara D. Bloomfield, MD  
Distinguished University Professor, Arthur G. James Cancer Hospital  
and Richard J. Solove Research Institute  
The Ohio State University Comprehensive Cancer Center  
1232 James Cancer Hospital  
300 W. 10th Ave  
Columbus, OH 43210  
USA  
*Chapter 3.*

Rainer Claus, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany  
*Chapters 3., 9.*

Barbara Deschler-Baier, MD  
Department of Internal Medicine II  
Division of Hematology and Medical Oncology  
University Hospital Würzburg  
Josef-Schneider-Str. 6/Haus C16  
97080 Würzburg  
Germany  
*Chapters 1., 8.*

Christiane Dobbelsstein, MD  
Division of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation  
Hannover Medical School  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
*Chapter 8.*

Christian Flotho, MD  
Professor, Division of Pediatric Hematology-Oncology  
Department of Pediatric and Adolescent Medicine  
University of Freiburg  
Mathildenstr. 1  
79106 Freiburg  
Germany  
*Chapter 11.*

Jürgen Finke, MD  
Professor, Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany  
*Chapter 10.*

Paul Fisch, MD  
Professor, Institute of Pathology  
University of Freiburg Medical Center  
Breisacherstr. 115a  
79106 Freiburg  
Germany  
*Chapter 2.*

Arnold Ganser, MD  
Professor, Division of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation  
Hannover Medical School  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
*Chapter 8.*

Norbert Gattermann, MD  
Professor, Division of Hematology, Oncology and Clinical Immunology  
Heinrich-Heine University  
Moorenstr. 5  
40225 Düsseldorf  
Germany  
*Chapters 5., 9.*

Ulrich Germing, MD  
Professor, Division of Hematology, Oncology and Clinical Immunology  
Heinrich-Heine University  
Moorenstr. 5  
40225 Düsseldorf  
Germany  
*Chapter 1.*

Aristoteles Giagounidis, MD  
Professor, Marien-Hospital Düsseldorf  
Rochusstraße 2  
40479 Düsseldorf  
Germany  
*Chapter 7.*



Peter Haas, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany  
*Chapter 4.*

Detlef Haase, MD  
Professor, Division of Hematology and Oncology  
Georg-August University  
Robert-Koch-Str. 40  
37075 Göttingen  
Germany  
*Chapter 3.*

Björn Hackanson, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany  
*Chapter 4.*

Wolf-Karsten Hofmann, MD  
Professor, Division of Hematology and Oncology  
University Hospital Mannheim  
Theodor-Kutzer-Ufer 1–3  
68167 Mannheim  
Germany  
*Chapter 5.*

Tina Jöckel, MD  
Cancer Immunology  
Peter MacCallum Cancer Institute  
Locked Bag 1 A'Beckett St  
Melbourne VIC 3006  
Australia  
*Chapter 9.*

H. Phillip Koeffler, MD  
Professor, Division of Hematology/Oncology  
University of California Los Angeles School of Medicine  
Cedars-Sinai Medical Center  
8700 Beverly Blvd.  
Los Angeles, CA 90048  
USA

*Chapter 3.*

Andrea Kündgen, MD  
Division of Hematology, Oncology and Clinical Immunology  
Heinrich-Heine University  
Moorenstr. 5  
40225 Düsseldorf  
Germany

*Chapter 9.*

Michael Lübbert, MD  
Professor, Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 9.*

Hilda Mangos, MD  
Dunedin School of Medicine  
University of Otago  
Dunedin 9016  
New Zealand

*Chapter 1.*

Reinhard Marks, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 10.*

Krzysztof Mrózek, MD, PhD  
Research Scientist  
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute  
The Ohio State University Comprehensive Cancer Center  
1232A James Cancer Hospital  
300 W. 10th Ave  
Columbus, OH 43210  
USA

*Chapter 3.*

Michael J. Müller, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 2.*

Uwe Platzbecker, MD  
Professor, Medical Clinic and Polyclinic I  
University Hospital  
Gustav-Carus University  
Fetscherstr. 74  
01307 Dresden  
Germany

*Chapter 6.*

Björn Rüter, MD  
Baird 6  
88400 Biberach an der Riß  
Germany

*Chapter 9.*

Valeria Santini, MD  
Professor, Division of Hematology  
University of Florence  
Largo Brambilla, 3  
50134 Florence  
Italy

*Chapter 4.*

Mikkael A. Sekeres, MD, MS  
Professor, Division of Hematologic Oncology and Blood Disorders  
Taussig Cancer Institute  
Cleveland Clinic  
Cleveland, Ohio 44195  
USA

*Chapter 1.*

Annette Schmitt-Gräff, MD  
Professor, Institute of Pathology  
University of Freiburg Medical Center  
Breisacherstr. 115a  
79106 Freiburg  
Germany

*Chapter 2.*

Dominik Schnersch, MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 6.*

Lewis R. Silverman, MD  
Professor, Division of Hematology/Oncology  
Mount Sinai School of Medicine  
Tisch Cancer Institute  
P.O. Box 1079  
One Gustave L. Levy Place  
New York, New York 10029  
USA

*Chapter 9.*

Laura Simons (née Debatin), MD  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 4.*

Christian Steidl, MD  
Department of Experimental Therapeutics  
Centre for Lymphoid Cancer  
675 West 10th Ave.  
Vancouver, V5Z 1L3  
Canada

*Chapter 9.*

Juliane Steinmann  
Division of Hematology, Oncology and Stem Cell Transplantation  
University of Freiburg Medical Center  
Hugstetterstr. 55  
79106 Freiburg  
Germany

*Chapter 6.*

Felicitas Thol, MD  
Division of Hematology, Hemostasis, Oncology and Stem Cell Transplantation  
Hannover Medical School  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany

*Chapter 8.*

Pierre Wijermans, MD PhD  
Department of Hematology  
Haga Hospital  
Leyweg 275  
2545 CH The Hague  
The Netherlands

*Chapter 9.*

Theo de Witte, MD PhD  
Professor, Tumour Immunology Lab  
Radboud University Nijmegen Medical Centre  
Route 278  
P.O. Box 9101  
Geert Grooteplein 26  
6525 GA Nijmegen  
The Netherlands

*Chapters 8., 10.*

Yataro Yoshida, MD  
Director, The Center for Hematological Diseases  
Takeda General Hospital  
28-1 Ishida-Moriminami  
Fiushimi-ku  
Kyoto 601-1495  
Japan  
*Chapter 9.*

# Contents

<b>1.</b>	<b>Epidemiology, classification and prognostic systems</b>	<b>22</b>
1.1.	Epidemiology of myelodysplastic syndromes	22
1.2.	Classifications of MDS	24
1.3.	Prognostic systems for myelodysplastic syndromes	26
1.4.	Epidemiology of acute myeloid leukemia	33
1.5.	Classifications of acute myeloid leukemia	36
1.6.	Prognostic systems for acute myeloid leukemia	38
1.7.	MDS and AML: a biological continuum	39
1.8.	References	40
<b>2.</b>	<b>Myelodysplastic syndromes and acute myeloid leukemia: morphologic and phenotypic aspects</b>	<b>46</b>
2.1.	The impact of morphology on the diagnosis of AML and MDS	46
2.2.	Myelodysplastic syndromes	47
2.2.1.	The World Health Organization Classification of MDS	47
2.2.2.	Morphologic features of MDS	48
2.2.2.1.	The peripheral blood in MDS	48
2.2.2.2.	The bone marrow in MDS	50
2.2.2.2.1.	Myelopoiesis	50
2.2.2.2.2.	Bone marrow architecture and stromal components in MDS	54
2.2.3.	Pitfalls in the diagnosis of MDS vs. dysplastic features in non-malignant conditions	56
2.3.	Acute myeloid leukemia	57
2.3.1.	The role of morphology in the integrated diagnosis of AML	57
2.3.2.	Morphology in AML with recurrent genetic abnormalities	58
2.3.3.	Acute myeloid leukemia, not otherwise specified (NOS)	64
2.3.4.	Myeloid proliferations associated with Down's syndrome	68
2.3.5.	Myeloid sarcoma	68
2.4.	References	69
<b>3.</b>	<b>Cytogenetics and molecular diagnostic genetics in MDS and AML</b>	<b>76</b>
3.1.	Chromosome abnormalities in MDS	76
3.1.1.	Unbalanced chromosomal abnormalities	77
3.1.2.	Balanced chromosomal abnormalities	78
3.1.3.	Correlations with morphologic findings	78
3.2.	Chromosomal abnormalities in AML	79
3.2.1.	Balanced changes – specific translocations and inversions: t(8;21), inv(16) or t(16;16), t(15;17), t(9;11), t(6;9), inv(3) or t(3;3), and t(1;22)	79
3.2.2.	Unbalanced changes – numerical abnormalities	81
3.2.3.	Unbalanced changes – deletions of 5q, 7q, and 20q	81
3.2.4.	Complex karyotypes	82
3.3.	Molecular alterations in MDS and AML	82
3.3.1.	Molecular changes in signal transduction	83
3.3.2.	Mutations and epigenetic dysregulation of cell cycle-regulating genes	86
3.3.3.	Mutations and transcriptional changes in transcription factors	87
3.3.4.	Genetic alteration of epigenetic modifiers	88
3.3.5.	Other molecular abnormalities	90

3.3.6.	mRNA and miRNA expression profiling.....	91
3.3.7.	Molecular characterization of the most frequent balanced cytogenetic rearrangements and the resultant fusion genes .....	93
3.3.8.	Molecular characterization of deletions on chromosome 5q in MDS.....	97
3.4.	<b>Present approaches to mutation discovery and high-throughput analyses.....</b>	<b>98</b>
3.4.1.	SNP chip analysis and Comparative Genomic Hybridization.....	98
3.4.2.	Exome and whole genome sequencing .....	99
3.5.	<b>References.....</b>	<b>99</b>

## **4. Supportive therapy for ineffective hematopoiesis in MDS and AML 110**

4.1.	<b>Transfusion management.....</b>	<b>110</b>
4.1.1.	Erythrocyte replacement .....	110
4.1.2.	Platelet substitution.....	110
4.1.3.	Granulocyte transfusion in severe neutropenia.....	111
4.2.	<b>Use of hematopoietic growth factors in bone marrow failure.....</b>	<b>111</b>
4.2.1.	Background.....	111
4.2.2.	Mechanism of action of erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) .....	111
4.2.3.	EPO and G-CSF: a synergistic effect in MDS .....	113
4.2.3.1.	A predictive model of the response of MDS patients to EPO and G-CSF.....	113
4.2.4.	Criteria for treatment response in MDS.....	113
4.2.5.	G-CSF in AML: decrease in duration of cytopenia after intensive chemotherapy .....	114
4.2.6.	G-CSF as inducer of differentiation in AML .....	114
4.2.7.	Thrombomimetic substances.....	115
4.3.	<b>References .....</b>	<b>116</b>

## **5. Treatment of iron overload in MDS 120**

5.1.	<b>Causes of iron overload in MDS .....</b>	<b>120</b>
5.2.	<b>Potential consequences of iron overload in MDS.....</b>	<b>121</b>
5.3.	<b>Clinical relevance of iron overload in MDS .....</b>	<b>121</b>
5.4.	<b>Indications for iron chelation in MDS .....</b>	<b>122</b>
5.5.	<b>Potential benefits of iron chelation in MDS .....</b>	<b>122</b>
5.5.1.	Decreased organ damage .....	122
5.5.2.	Diminished risk of infections.....	123
5.5.3.	Improved hematopoietic function .....	123
5.5.4.	Decreased rate of leukemic transformation .....	124
5.5.5.	Improved outcome of hematopoietic stem cell transplantation.....	125
5.5.6.	Survival benefit .....	125
5.6.	<b>Diagnosis of iron overload in patients with MDS .....</b>	<b>125</b>
5.7.	<b>Treatment with iron chelating agents .....</b>	<b>126</b>
5.7.1.	Deferoxamine (desferrioxamine, Desferal™).....	126
5.7.2.	Deferiprone (L1, Ferriprox™).....	127
5.7.3.	Combination of deferoxamine (DFO) and deferiprone (DFP) .....	127
5.7.4.	Deferasirox (ICL670, Exjade™) .....	128
5.8.	<b>References .....</b>	<b>130</b>



<b>6.</b>	<b>Low-dose chemotherapy and kinase inhibition as treatment options in AML and MDS</b>	<b>136</b>
6.1.	Low-dose chemotherapy as non-intensive specific therapy in elderly patients	136
6.1.1.	Low-dose cytarabine (LDC) in MDS and AML	136
6.1.2.	Melphalan	138
6.1.3.	Hydroxyurea in CMML	138
6.1.4.	Other chemotherapeutic drugs	138
6.2.	Kinase inhibition as a therapeutic approach in the treatment of acute myeloid leukemia	138
6.2.1.	FMS-like tyrosine kinase 3 (Flt3)	138
6.2.2.	Flt3 inhibitors	139
6.2.3.	c-KIT	140
6.2.4.	Inhibition of mitotic kinases as a treatment approach	141
6.3.	References	143
<b>7.</b>	<b>Inhibition of angiogenesis as a treatment approach in MDS and AML</b>	<b>148</b>
7.1.	Influence of angiogenesis in AML and MDS	148
7.2.	Anti-angiogenic compounds in the treatment of hematological neoplasms	149
7.2.1.	Thalidomide	150
7.2.2.	Lenalidomide	150
7.3.	Summary	155
7.4.	References	155
<b>8.</b>	<b>Standard chemotherapy and autologous stem cell transplantation</b>	<b>160</b>
8.1.	Intensive treatment options in patients with MDS and AML after MDS	160
8.2.	Differences between de novo AML, AML from MDS and MDS	160
8.3.	The standard: induction chemotherapy	160
8.4.	Autologous stem cell transplantation	162
8.5.	The challenge: individual assignment of treatment	164
8.6.	References	166
<b>9.</b>	<b>Epigenetic therapy</b>	<b>172</b>
9.1.	DNA methylation and chromatin modifications	172
9.1.1.	DNA methylation: a key mechanism of gene repression	172
9.1.2.	Regulatory changes in chromatin structure through histone modifications	172
9.1.3.	Target genes	173
9.2.	Azanucleosides	174
9.3.	Clinical studies with DNA demethylating substances	174
9.3.1.	Treatment of MDS patients with azacitidine	174
9.3.2.	Treatment of MDS patients with 5-aza-2'-deoxycytidine (decitabine)	177
9.3.3.	Treatment of AML patients with azacitidine	179
9.3.4.	Treatment of AML patients with 5-aza-2'-deoxycytidine (decitabine)	179
9.4.	Histone deacetylase (HDAC) inhibitors	180
9.4.1.	Drug classes	180
9.4.2.	Clinical studies with HDAC inhibitors	181
9.5.	Studies with all- <i>trans</i> retinoic acid in patients with MDS and AML	183
9.6.	References	185

<b>10.</b>	<b>Allogeneic transplantation: extending the therapeutic spectrum by dose-reduced conditioning</b>	<b>192</b>
10.1.	Procedure .....	192
10.1.1.	HLA compatibility .....	192
10.1.2.	Stem cell source .....	192
10.1.3.	Immunological aspects of allografting .....	192
10.1.4.	Conditioning .....	193
10.2.	Results .....	194
10.2.1.	Increasing frequency of allo-HSCT .....	194
10.2.2.	Allogeneic HSCT with high-dose conditioning .....	194
10.2.2.1.	AML .....	194
10.2.2.2.	MDS .....	196
10.2.3.	Allogeneic HSCT with toxicity-reduced conditioning .....	198
10.3.	Other therapeutic aspects .....	198
10.3.1.	Patient age .....	198
10.3.2.	Dose of toxicity-reduced conditioning .....	199
10.3.3.	Indications for allogeneic HSCT .....	199
10.4.	References .....	200
<b>11.</b>	<b>A pediatric perspective on myelodysplastic syndromes</b>	<b>204</b>
11.1.	Classification .....	204
11.2.	Diagnosis .....	205
11.3.	Pathophysiology .....	207
11.4.	Treatment .....	208
11.5.	References .....	210
	<b>Index</b>	<b>213</b>



# **Epidemiology, classification and prognostic systems**

# 1. Epidemiology, classification and prognostic systems

## 1.1. Epidemiology of myelodysplastic syndromes

Compared to many solid tumor, myelodysplastic syndromes (MDS) are rare. In older adults, however, they are among the most common hematological diseases. While they can appear in childhood and adolescence, their peak incidence rate occurs after the age of 80 years [1, 2].

### ■ Incidence and Prevalence

The actual incidence rate of MDS is unknown in many countries, but some progress has been made. Important reasons for these are:

- Unified recording of the disease has only been possible since 1982, after the French-American-British (FAB) group established uniform diagnostic criteria [10].
- Numerous causes of cytopenia remain undiscovered, particularly in advanced age, because a bone marrow examination often is not performed to determine the cause. Among patients with unexplained anemia, as many as 17% have a macrocytic anemia, leukopenia, or thrombocytopenia – peripheral blood findings typical of MDS.
- Central registries for recording new cases of MDS at a national level are not uniformly maintained around the world.

In 2001 the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and the Centers for Disease Control and Prevention (CDC) started to track incidence rates of MDS. Based on these SEER data, collected from 2001-2003, the age-adjusted incidence rate of MDS in the United States (US) was estimated to be 3.4 per 100,000 people, which translates to approximately 10,000 new cases per year [3]. The incidence rate over these 3 years increased from 3.3 to 3.6, in large part likely due to improved reporting practices within cancer registries. Incidence rates were lowest for people less than 40 years of age at 0.14 per 100,000 and 36 per 100,000 for patients more than 80 years of age [4]. This figure is considered to be an underestimate. The incidence of MDS using a novel claims-based algorithm re-

ported a high number of uncaptured cases by one cancer registry, and claimed an annual incidence of MDS of 75 per 100,000 persons 65 years or older, far higher than the 20 per 100,000 reported by SEER using the same sample [5]. Although Goldberg et al. reported the 2003 incidence rate among US Medicare Beneficiaries to be as high as 162 per 100,000, this is felt to be an overestimate related to inaccuracies in diagnostic coding [6]. The US incidence rate is similar to that reported in Western European countries such as England/Wales and Sweden 3.6/100,000, Germany 4.1/1000,000, and France 3.2 per 100,000 but higher than Japan's rate of 1.0/1000,000 [1, 7, 13, 14].

Prior to 2001, data on the incidence rate of MDS was recorded in local/regional registries, and did not represent the full scope of the disease. In addition, historic databases relied on the FAB MDS classification, rather than the WHO classification introduced in 1999 and revised in 2001 and 2008 [8, 9]. Therefore a precise comparison with older epidemiological studies is challenging, particularly when one factors in the difficulty of making the diagnosis pathologically, introducing the potential for misclassification. Despite all these uncertainties, there are some European regional registries that have allowed valid statements to be made regarding the incidence rate of MDS.

One large study from the United Kingdom [11] reported an incidence rate of 3.6/100,000 yearly, among 16 million people. People older than 80 years were not included in this study, and no central cytomorphological investigation of bone marrow blood was undertaken. A subsequent study in the UK over a 10-year period did include elderly patients, and found an incidence rate of 61/100,000 for male patients, 28/100,000 for females and 38/100,000 for both groups among patients 80 and older. Another large study from Düsseldorf, Germany recorded all new cases of MDS over two 10-year periods [1, 2]. The incidence rate was similar, at 4-5 new cases of the disease/100,000 of the population yearly, and a strong relationship with age was also identified. Moreover, the incidence rate of MDS was accurately tracked for a total of 26

years. Recently Neukirchen et al. reported a crude incidence rate of 4.15/100,000/year and the point prevalence per 100,000 persons of 7 based on data from the Düsseldorf MDS Registry [12].

While initially there was the impression that the incidence of MDS was increasing in Germany, since the end of the 1980s no further rise in the incidence of MDS has been found. This is primarily because the number of cytological investigations of bone marrow in elderly patients abruptly increased in the first few years of the survey, whereas since the end of the 1980s there has not been any further increase in the frequency of diagnostic procedures.

A Swedish study [13] found a similar incidence rate of 3.6/100,000, and three consecutive French studies [14, 16] reported an incidence rate of 3.2/100,000 of the population yearly. Another French study in the Basque region [17] found a somewhat higher incidence rate of 7.7/100,000, while a study from Bournemouth [18] showed the highest incidence rate, at 12.6 new cases of the disease per year, which may be due to the municipal region of Bournemouth having a large population of retired people (similar to the region in the U.S. study reporting an incidence rate of 75/100,000) [5]. Another British study [19] likewise estimated the incidence rate as being somewhat higher, at 9.3/100,000 of the population. A Japanese study [12] surprisingly showed a much lower incidence rate of 1/100,000 per year, but only reviewed a 1-year period and thus was unable to give any information about a possible change in the incidence rate.

Estimates as to the number of treatment-associated or secondary MDS (sMDS) are also fairly similar. Approximately 10% of MDS patients have secondary disease, most commonly following therapy with ionising radiation or cytotoxic drugs or leukaemogenic substances i.e. alkylating agents and topoisomerase inhibitors, for other cancers [1, 20, 21]. The latency period for sMDS after exposure to alkylating agents or radiation therapy is 5-7 years. The risk appears to be dose-dependent [22, 23], and is associated with unbalanced translocation involving chromosome 5 or chromosome 7, or complex cytogenetics [24]. MDS following topoisomerase inhibitors are less common, with a latency period of approximately 2 years [25], and is associated with a balanced translocation involving 11q23 (the MLL gene). Long-term prognosis is be-

lieved to be poor for either type of secondary MDS [26, 27].

It is difficult to identify accurate prevalence statistics for MDS i.e. the numbers of those living with the disease, as opposed to new diagnoses. Preliminary data from Germany reveals a prevalence rate of 12.4 per 100,000 people [28]. If we assume that the incidence, and thus the prevalence rates between the U.S. and Germany are similar, this would translate to approximately 60,000 people with MDS in the US. However, this is thought to be an underestimate. Guralnik et al. reported the prevalence of anemia in the U.S. in 2004, based on 2000 blood samples collected from people 65 years of age or older as part of the third National Health and Nutrition Examination Survey [29]. The overall prevalence of anemia was 10.6%. Within the category "unexplained anemia" 7% of people had a macrocytic anemia, leukopenia or thrombocytopenia – peripheral blood findings typical of MDS. This would translate to 170,000 people living with MDS in the U.S. Thus, while a prevalence of 170,000 can be assumed to be an overestimate, a rate of 60,000 people likely underestimates the impact of the disease.

## ■ Etiology

The etiology of the vast majority (>90%) of myelodysplastic syndromes is completely unclear. Pre-existing systemic hematological diseases such as aplastic syndrome or paroxysmal nocturnal hemoglobinuria (PNH) are identified in extremely rare cases. Genetic factors (Down syndrome, Noonan syndrome, Shwachman-Diamond syndrome, Fanconi anemia, and others) can be found in very few instances. While some case reports document MDS in advanced aged with a familial increase in incidence because of genetic constitutional abnormalities, e.g. of chromosome 5 and 7, these cases are rare enough to make the statement to patients that MDS does not run in families.

Environmental factors that can favor the development of MDS include ionising radiation, alkylating substances, and other chemotherapy agents as well as massive exposure to organic solvents and their derivatives. This has been well-described in patients working in the rubber and oil industries. Case-control studies confirm an increased risk of MDS from exposure to agricultural chemicals (insecticides, pesticides, herbicides or fertiliser, with